Please assess the completion status of the following clinical trial:

Trial Title: SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed renal cell carcinoma of clear cell histology with metastases~* Evidence of measurable disease by radiographic technique~* Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1~Exclusion Criteria:~* Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC~* History of or known brain metastases~* Serious acute or chronic illness or recent history of significant cardiac abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).